Chiesi will pay $27 per share for KalVista Pharmaceuticals, which has an approved drug for hereditary angioedema. This acquisition marks the fifth biotech purchase this week, signaling strong interest in innovative therapies.
Why it matters. The deal underscores the pharma sector's aggressive pursuit of new oral therapies for rare diseases, particularly as competition increases from companies like Takeda.
Our readExpect further consolidation in the rare disease space as companies seek growth through acquisitions.
Source · BioPharma Dive
Novartis has announced plans for a new factory in North Carolina, completing its $23 billion investment in US manufacturing. This facility aims to boost the production capacity for its growing portfolio.
Why it matters. This facility aims to boost the production capacity for its growing portfolio.
Our readNovartis is positioning itself to capitalize on the US market, signaling confidence in future growth.
Source · Endpoints News
The FDA is set to hold its first oncology advisory committee meeting in nine months, focusing on AstraZeneca's new cancer therapies. This meeting could influence upcoming drug approvals and market strategies.
Why it matters. This meeting could influence upcoming drug approvals and market strategies.
Our readAstraZeneca's upcoming adcomm could be a pivotal moment for its oncology portfolio, especially in a crowded market.
Source · Endpoints News
Avalyn Pharmaceuticals has raised $300 million in its IPO to develop inhalable therapies for pulmonary fibrosis. The funds will accelerate its clinical programs targeting this underserved area.
Why it matters. The funds will accelerate its clinical programs targeting this underserved area.
Our readAvalyn's successful IPO reflects investor confidence in innovative solutions for pulmonary conditions.
Source · BioPharma Dive
Ecolab Life Sciences has launched its Bioprocessing Applications Laboratory in Korea to support local biomanufacturers. This facility aims to enhance collaboration and expedite biomanufacturing processes across Asia.
Why it matters. This facility aims to enhance collaboration and expedite biomanufacturing processes across Asia.
Our readEcolab's new lab reflects a strategic move to strengthen its foothold in the rapidly evolving bioprocessing sector.
Source · GEN News